A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Clinical trial NCT02268851 · COMPLETED
Trial details
- NCT number
- NCT02268851
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-01
- Primary completion
- 2018-05-01
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.